MPO and glomerulonephritis: In experimental anti-MPO glomerulonephritis, genetic or pharmacologic C5aR1 targeting resulted in attenuated TH1 immunity and increased frequency of regulatory T cells (Tregs) eventually mitigating autoimmunity to MPO (48) (Figure 1A).